Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Simultaneous Assay of Immunoreactive β-Lipotropin, γ-Lipotropin, and β-Endorphin in Plasma of Normal Human Subjects, Patients with ACTH/Lipotropin Hypersecretory Syndromes, and Patients undergoing Chronic Hemodialysis
Xavier Y. Bertagna, William J. Stone, Wendell E. Nicholson, Charles D. Mount, David N. Orth
Xavier Y. Bertagna, William J. Stone, Wendell E. Nicholson, Charles D. Mount, David N. Orth
View: Text | PDF
Research Article

Simultaneous Assay of Immunoreactive β-Lipotropin, γ-Lipotropin, and β-Endorphin in Plasma of Normal Human Subjects, Patients with ACTH/Lipotropin Hypersecretory Syndromes, and Patients undergoing Chronic Hemodialysis

  • Text
  • PDF
Abstract

We have studied the relative concentrations of the human immunoreactive (IR) peptides γ-lipotropin (hγLPH, [1-58]hβLPH), β-lipotropin (hβLPH), and β-endorphin (hβEND, [61-91]hβLPH) using gel exclusion chromatography together with a specific radio-immunoassay (RIA) for hγLPH and a RIA that (because hβEND is the COOH-terminus of the hβLPH molecule) measures both hβEND and hβLPH on an equimolar basis. In normal subjects, basal plasma IR-hγLPH was often undetectable (<12.5 fmol/ml), but ranged up to 21 fmol/ml, and IR-hβEND/hβLPH was 10.8±0.7 fmol/ml; previous studies by others suggest that most of the IR-hβEND/hβLPH was probably hβLPH. Both IR-hγLPH and IR-hβEND/hβLPH were significantly elevated (P < 0.001) in patients undergoing chronic hemodialysis (101.5±12.7 and 23.8±2.0 fmol/ml, respectively). Their IR-hγLPH coeluted with standard hγLPH as a single peak, and IR-hβEND/hβLPH coeluted with hβLPH; no distinct peak of IR-hβEND was observed. In patients with ACTH/LPH hypersecretion due to Addison's disease, Nelson's syndrome, or ectopic ACTH syndrome, IR-hγLPH and IR-hβEND/hβLPH were both elevated, and IR-hβEND/hβLPH eluted as two peaks, one coeluting with hβLPH and the other with hβEND. The molar concentrations of all three peptides were significantly correlated with one another. The lower concentrations of endogenous IR-hβEND observed may be due in part to its apparent shorter plasma half-life, as estimated in an Addison's patient given a cortisol infusion. The biologic significance of these three peptides in circulating blood is still unknown. The increased levels of hβLPH and hγLPH in plasma of patients with chronic renal failure suggest that the kidney may be an important organ for their metabolism.

Authors

Xavier Y. Bertagna, William J. Stone, Wendell E. Nicholson, Charles D. Mount, David N. Orth

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts